Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Sanofi: Clinical Trials & FDA Approval Profile

Sanofi (Paris, FR / Cambridge, MA) sponsors 328 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 103 active protocols (48 recruiting now), 152 completed protocols, and 132 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)22.3%
Median Closed Enrollment vs National (145 pts)223 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Sanofi
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)328
Active Pipeline (Recruiting Now)103 (48)
Completed vs Stopped Early152 / 73 (22.3%)
Median Closed Actual Enrollment223 participants
Physical Hospital Site Disclosure27.3% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals132 (11 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Sanofi
Hospital Research SiteLocationShared Protocols
Washington University and Siteman Cancer CenterSaint Louis, MO21
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CA21
University of Michigan Rogel Cancer CenterAnn Arbor, MI20

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Sanofi
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07325292Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple SPhase IIIRECRUITING
NCT07184944A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's DiseasePhase IIIRECRUITING
NCT07185009A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative ColitiPhase IIIRECRUITING
NCT06290141A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With ChronPhase IIIRECRUITING
NCT07184996An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative ColitisPhase IIIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sanofi across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Sanofi Interactive Dossier, benchmark peers in Infectious Disease and Vaccines, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI